![](https://static.scientificamerican.com/sciam/cache/file/E1F4509A-6DFA-4765-A4BC2AD37C0E2866_agenda.jpg?w=275&h=154&fit=crop)
NIH-Funded Trials Dip, Industry Trials on the Rise
Adjusted for inflation, NIH budget has fallen by 14 percent since 2006, which may explain some of the decrease
Adjusted for inflation, NIH budget has fallen by 14 percent since 2006, which may explain some of the decrease
The new findings do not prove SSRIs cause autism, but they raise more questions about taking such medications late in pregnancy
Soaring levels of drug use in livestock fuels concern about resistant bacteria, human health
Lawmakers investigating how mergers may stoke price hikes at companies including Valeant, Turing
The eggs of the genetically engineered animal contain an enzyme that can treat a rare disease
If you find yourself taking headache medication more often than you'd like, try these drug-free approaches next time a headache looms
Preliminary studies reveal harmful effects of highly potent cannabis, but causal links remain unclear
New data shows monoclonal antibodies may indeed slow the disease when given early
A clinical trial will look at the neurological structure and function of people who have attempted suicide
A live webcast Wednesday evening will demonstrate how radioactive chemicals can provide a window on disease within the body
Scientists alarmed by potential spread of gene that makes bacteria highly resistant to last-resort antibiotics
Survey of 10,000 people across 12 countries reveals widespread misconceptions the drugs
The widespread practice of giving antibiotics to healthy livestock to promote growth and prevent disease is making the drugs ineffective, the American Academy of Pediatrics says
Fatalities from causes like heart disease, cancer and stroke dropped 43 percent between 1969 and 2013
Synthetic cells get one step closer to reality
The decision is likely to delay a possible broad roll-out of the shot for between three and five years
A review of studies that assess clinical antidepressants shows hidden conflicts of interest and financial ties to corporate drugmakers
The new libido pill will likely lure users for whom it was not approved: women taking antidepressants
Genetic sequencing of the virus suggests it has been circulating for two years in an area with low immunization rates
Experts are concerned that the illness, which is increasingly linked to a disorder that causes paralysis, may become a problem in the U.S.
Support science journalism.
Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account